BioNTech Valuation
| 0A3M Stock | USD 113.60 7.06 6.63% |
At this time, the firm appears to be fairly valued. BioNTech SE shows a prevailing Real Value of $110.31 per share. The current price of the firm is $113.6. Our model approximates the value of BioNTech SE from analyzing the firm fundamentals such as Profit Margin of 0.48 %, current valuation of 9.89 B, and Return On Equity of 0.24 as well as examining its technical indicators and probability of bankruptcy.
Price Book 1.3611 | Enterprise Value 9.9 B | Enterprise Value Ebitda 110.8146 | Price Sales 3.4023 | Forward PE 7.0721 |
Fairly Valued
Today
Please note that BioNTech's price fluctuation is very steady at this time. Calculation of the real value of BioNTech SE is based on 3 months time horizon. Increasing BioNTech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioNTech stock is determined by what a typical buyer is willing to pay for full or partial control of BioNTech SE. Since BioNTech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioNTech Stock. However, BioNTech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 113.6 | Real 110.31 | Hype 113.42 | Naive 110.4 |
The intrinsic value of BioNTech's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence BioNTech's stock price.
Estimating the potential upside or downside of BioNTech SE helps investors to forecast how BioNTech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioNTech more accurately as focusing exclusively on BioNTech's fundamentals will not take into account other important factors: BioNTech Cash |
|
BioNTech Total Value Analysis
BioNTech SE is presently expected to have takeover price of 9.89 B with market capitalization of 31.25 B, debt of 28.1 M, and cash on hands of 914.9 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BioNTech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.89 B | 31.25 B | 28.1 M | 914.9 M |
BioNTech Investor Information
About 65.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.36. In the past many companies with similar price-to-book ratios have beat the market. BioNTech SE has Price/Earnings To Growth (PEG) ratio of 0.05. The entity recorded earning per share (EPS) of 18.0. The firm last dividend was issued on the 6th of June 2022. Based on the key indicators obtained from BioNTech's historical financial statements, BioNTech SE is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.BioNTech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioNTech has an asset utilization ratio of 16.6 percent. This suggests that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that BioNTech SE is more efficient with each dollar of assets it utilizes for everyday operations.BioNTech Ownership Allocation
BioNTech holds a total of 239.77 Million outstanding shares. BioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.11 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.BioNTech Profitability Analysis
The company reported the revenue of 3.82 B. Net Income was 930.3 M with profit before overhead, payroll, taxes, and interest of 16.07 B.About BioNTech Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of BioNTech SE. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of BioNTech SE based exclusively on its fundamental and basic technical indicators. By analyzing BioNTech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of BioNTech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioNTech. We calculate exposure to BioNTech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioNTech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.2 B | 5.8 B |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.